# Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

> **NCT00274495** · PHASE4 · TERMINATED · sponsor: **Beth Israel Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Hepatitis C Infection
- Fatty Liver

## Interventions

- **DRUG:** Rosiglitazone and Pegasys/Ribavirin

## Key facts

- **NCT ID:** NCT00274495
- **Lead sponsor:** Beth Israel Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2007-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00274495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00274495, "Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00274495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*